Anti-Estrogens
First-line treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| Retrospective Study: Adjuvant Hormone Therapy in LGSC | Two sites | Anastrozole, Letrozole, Tamoxifen | Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival? | Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery PFS: Not Reached (41 months follow up) Pub 2017 |
Maintenance after first-line therapy: Treatment to prevent relapse after complete or partial response to therapy
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in NCCN Guidelines | ||||
| Retrospective Study: Hormonal Maintenance in LGSC | II | Anastrozole, Letrozole, Tamoxifen | Retrospective analysis of Hormonal Maintenance Therapy for Patients With LGS Ovarian Cancer | Significantly longer PFS with hormonal maintenance therapy (HMT) vs. observation (OBS) in Low Grade Serous OC patients HMT vs OBS: PFS: 64.9 vs 26.4 months* pub 2017 |
*Statistically significant result